BioCryst Pharmaceuticals, Inc. (BCRX)
8.45
+0.02
(+0.24%)
USD |
NASDAQ |
Jun 09, 14:04
BioCryst Pharmaceuticals SG&A Expense (Quarterly) : 94.55M for March 31, 2026
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Dyne Therapeutics, Inc. | 24.39M |
| Taysha Gene Therapies, Inc. | 9.677M |
| Agenus, Inc. | 6.86M |
| Amgen, Inc. | 1.602B |
| Imunon, Inc. | 1.969M |